Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb, Multicenter, Single-Arm Open-Label Study, Supporting the Development and the Validation of the MATHYS Scale (Multidimensional Assessment of THYmic States) in a Population of Bipolar Patients Treated With Olanzapine, Either in-Label (Manic and Mixed Patients) and Off-Label (Hypomanic and Bipolar Depression)

NCT00259272 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00259272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00259272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb, Multicenter, Single-Arm Open-Label Study, Supporting the Development and the Validation of the MATHYS Scale (Multidimensional Assessment of THYmic States) in a Population of Bipolar Patients Treated With Olanzapine, Either in-Label (Manic and Mixed Patients) and Off-Label (Hypomanic and Bipolar Depression)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2005
Completion date
May 31, 2008
Enrollment
141 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder i or ii